2024-03-12
NeuroX1
www.neurox1.comHeadquarters
Austin, TX
Employee Count
10
Year Founded
2021
Amount raised
$2.12 million
Business model
B2B; Upfront payment for early discovery and then progressively increasing milestones as drug assets progress through each phase of clinical development, plus a royalty if approved.
Early traction
3 industry co-development partnerships and 2 academic collaborations.
Traditional drug discovery methods are slow, expensive, and have high failure rates.
The average drug discovery takes 10-15 years.
The economic burden exceeds more than $655B annually.
The failure rate of drugs for neurodegenerative diseases is about 99%.
This week’s company leverages AI to identify targets of neurological diseases and generate drug candidates.
NeuroX1 utilizes AI to identify drivers of neurological diseases to improve the drug discovery process.
Drivers: The platform analyzes biological data to uncover underlying causes behind brain diseases.
Discovery: NeuroX1 designs computational compounds, potentially speeding up the time consuming process of drug discovery.
Bulleted Version
Market Opportunity: The neurological disorder drugs market is expected to grow nearly 5% annually due to the rising prevalence of diseases among aging populations and demand for treatments.
Drug Discovery: NeuroX1's use of generative chemistry dramatically shortens the time and reduces the cost needed to find new drugs, representing a major leap forward in medicine development.
Innovative Business Model: The company’s B2B model, which combines upfront payments with milestones and royalties, aligns incentives across the drug development process while fostering innovation.
AI Hallucinations: Like other advanced algorithms, NeuroX1’s platform might generate chemically valid but biologically unproven structures, potentially leading to redirected research paths and careful client expectation management.
Non-Recurring Revenue: While NeuroX1 has an innovative monetization model, its dependence on performance could delay unrealized annualized revenue.
Algorithm Overlap: If NeuroX1's AI learns and adapts from multiple lab projects simultaneously, there's a risk that one project's discovery process could inadvertently influence another's, diluting the exclusive value of expensive, proprietary research for organizations.
Cradle: Backed by Kindred Capital, Index Ventures, and others.
CHARM Therapeutics: Backed by NVentures, General Catalyst, Khosla Ventures, F-Prime Capital, and others.
Aquemia: Backed by Wendel Growth, Bpifrance, Eurazeo, and others.
Pangea Botanica: Backed by No Label Ventures, Seaside Ventures, Kadmos Kapital, and others.
WhyNeuroX1
By slashing costs, speeding up development, and boosting the success rate of finding new treatments for brain disorders, NeuroX1 could be the necessary cure for the pharmaceutical industry.
*Nothing in this content constitutes investment or legal advice. Conduct independent diligence and consult professional advisers before making investment decisions.*
Explore
other features
Austin, TX
2026-03-31
Polygraf
Polygraf is a real-time control layer that sits between employees and AI tools, ensuring companies can use AI freely without losing control of their data.
Business model
Selling directly to enterprises & selling tools to businesses for integration within their own security products
NYC
2026-03-17
Licensed To Glow
Licensed To Glow is a subscription marketplace where consumers pay a flat fee to discover, book, and return to trusted beauty and aesthetics providers.
Business model
Subscription fees
San Francisco, CA
2026-03-03
Corvera
Corvera builds AI agents that forecast demand, manage inventory, and execute the operational work required to scale a CPG brand.
Business model
Subscription fee